C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease

Deng, Zaichun; Zhao, Peng; Cao, Chao; Sun, Shifang; Zhao, Feng; Lu, Chao‐Yue; Ma, Hongying

doi:10.3892/etm.2013.1441

Cited by 28 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…72 Dahl et al 73 showed that C-reactive protein levels in the stable state were a strong long-term predictor of future outcomes in subjects with COPD. We found increased C-reactive protein levels in subjects with COPD, which is in agreement with results obtained by Dahl et al, 73 Akbulut et al, 74 van Durme et al, 75 and Deng et al, 76 who reported C-reactive protein levels higher in stable subjects with COPD and suggested its utility as a long-term predictor of future outcomes. C-reactive protein levels of 2,896.89 Ϯ 1,739.76 ng/mL in subjects with normal lung function (see Table 4) are similar to those reported by Akbulut et al 74 SPD, found predominantly in the endoplasmic reticulum of type-2 alveolar cells and in the secretory granules of Club cells in lungs, 36 has the highest expression in the distal airways and alveoli in human tissues and plays a central role in pulmonary host defense.…”

Section: Discussionsupporting

confidence: 82%

Diagnostic Utility of Biomarkers in COPD

Ambade¹,

Sontakke

Barthwal³

et al. 2015

Respir Care

View full text Add to dashboard Cite

BACKGROUND: COPD will become the third leading cause of death by 2020. There are many situations in which spirometry, the primary tool for diagnosis of COPD, cannot be performed, and thus, the staging and status of these patients cannot be determined. To date, there is no known biochemical marker used for diagnosing COPD. This study aimed to explore the utility of biomarkers for diagnosis of COPD. METHODS: This was an observational study composed of 96 stable subjects with COPD and 96 subjects with normal lung function. Each group contained an equal number of smokers and nonsmokers. Serum levels of superoxide dismutase 3, glutathione peroxidase, catalase, ceruloplasmin ferroxidase activity, C-reactive protein, and surfactant protein D (SPD) were estimated. Ferroxidase activity was estimated by a kinetic method, whereas the other analytes were measured by enzyme-linked immunosorbent assay. The cutoff value, sensitivity and specificity at the cutoff value, and area under the curve for each analyte were determined from receiver operating characteristic curve. RESULTS: Significantly decreased superoxide dismutase 3 and increased ferroxidase activity, SPD, glutathione peroxidase, and C-reactive protein levels were found in subjects with COPD. For all subjects and nonsmoking subjects with COPD, the area under the curve was highest for ferroxidase activity, followed by glutathione peroxidase, SPD, and C-reactive protein, with a sensitivity and specificity of > 73%. For smoking subjects with COPD, the area under the curve was highest for SPD, followed by glutathione peroxidase, ferroxidase activity, and C-reactive protein, with a sensitivity and specificity > 67%. Some combinations of markers were found to give either a sensitivity or specificity of > 95%, which can be utilized to rule in and rule out COPD. CONCLUSIONS: Biomarkers can be reliably utilized in the diagnosis of COPD. Of all the markers, SPD appears to be the most promising in smokers, whereas ferroxidase activity shows promise in nonsmokers. To rule out COPD, ferroxidase activity or glutathione peroxidase can be potentially useful, whereas to rule in COPD, ferroxidase activity and glutathione peroxidase appear to be the most promising combination in both nonsmoking and smoking subjects.

show abstract

Section: Discussionsupporting

confidence: 82%

Diagnostic Utility of Biomarkers in COPD

Ambade¹,

Sontakke

Barthwal³

et al. 2015

Respir Care

View full text Add to dashboard Cite

show abstract

“…[12] In our study, serum CRP levels were found to be higher in stable COPD patients (13.55+10.83 vs. 2.07+0.82 mg/lit, p<0001) than in well matched healthy control subjects that was statistically highly significant. This finding is in accord with studies conducted by Abolhassan Halvani et al [13] , Broekhuizen et al [14] , Biljana Lazovic et al [15] and Deng et al [16] who concluded that COPD itself can increase the serum CRP which is a major factor causing extra-pulmonary complications and it may be used as a long term predictor of future outcomes. A meta-analysis by Y Zhang, H Bunjhoo, W Xiong et al [17] suggested that patients with stable COPD had higher serum CRP concentrations than healthy controls and that the serum CRP concentration might be an indicator of disease severity.…”

Section: Discussionsupporting

confidence: 79%

Study of Prognostic Association of C-Reactive Protein (A Biomarker) with Clinically Important Predictors of Outcome in Stable and Unstable COPD Patients

2016

AIMDR

View full text Add to dashboard Cite

Background: COPD is characterized by persistent airflow limitation that is progressive and is associated with enhanced chronic inflammatory response in the airways to noxious particles or gases. It has both systemic and pulmonary effects. Since COPD deaths estimated to increase by 30% in next 10 years, cost of treatment will be a heavy burden on global economy. The costs are proportional to pulmonary and extra pulmonary components of the disease. Methods: In this study, we examined 100 patients of COPD, out of which 80 were stable and 20 were unstable. Results: CRP levels were found to be increased in cases more than in controls (13.55+10.83 vs. 2.07+0.82 mg/lit, p<0.001), the levels being higher in unstable patients than in stable patients (33.78+7.74 vs. 8.50+1.81 mg/lit, p<0.001). We also submitted the patients to MMRC dyspnoea scale and found that CRP is positively correlated with MMRC dyspnoea scale (r=0.638, p<0.001) and was inversely correlated with 6-minute walk distance (r= -0.364, p<0.001). There was a significant positive correlation of CRP with BODE index (r=0.780, p<0.001). Conclusion: The study is valuable in detecting the severity of COPD cases both in stable and unstable conditions and to forecast the future morbidity and mortality outcome of such cases.

show abstract

“…A correlation of r = 0.99 was found with the respiratory indices that shows a strong inverse correlation. Such higher value of CRP was also found in several other studies reported outside India [9,10].…”

Section: Discussionsupporting

confidence: 72%

Biochemical Markers of Cardiac Risk and Their Relation to Spirometric Indices of Airway Obstruction Among COPD Patients

Mukherjee¹

2017

AJIM

View full text Add to dashboard Cite

Abstract:Monitoring of the cardiac status of COPD (Chronic Obstructive Pulmonary Disease) and comparing them with their respiratory indices thought to be predictive markers of the general health of these patients and be indicative, even prognostic, of any impending deterioration. This study was destined to evaluate various aspect of serum prognostic factors in COPD patients. This study was conducted over a period of six months. During this time biochemical markers of 43 (34 male and 9 female) patients suffering from COPD were collected and compared them with those of 40 healthy case control subjects. The Methodology and Exclusion Criteria were strictly adhered to, and based on the statistical analysis shown below the final results were arrived at, which have been discussed at length below. The relation between smoking and COPD found to be controversial, but smoking none the less has a detrimental effect on the respiratory indices and thus, cessation of smoking would definitely benefit these patients, although the extent of the benefit is a matter of debate and further study. As for the individual markers, serum CRP and plasma homocysteine are definitely important as prognostic markers, as well as the indicators of the present stage of the disease. Serum Lipoprotein (a) was not found to be very effective indicator in this study. Homocysteine as well as CRP but not lipoprotein (a), as cardiac indices is inversely related to the respiratory indices of a COPD patient. Measurement of these parameter might help in prognostic evaluation in those patients.

show abstract

C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease

Cited by 28 publications

References 24 publications

Diagnostic Utility of Biomarkers in COPD

Diagnostic Utility of Biomarkers in COPD

Study of Prognostic Association of C-Reactive Protein (A Biomarker) with Clinically Important Predictors of Outcome in Stable and Unstable COPD Patients

Biochemical Markers of Cardiac Risk and Their Relation to Spirometric Indices of Airway Obstruction Among COPD Patients

Contact Info

Product

Resources

About